Table 2 Change in efficacy outcomes after 16, 32 and 52 weeks—all showed a significant decrease.

From: A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world

 

Baseline

After 16 weeks

After 32 weeks

After 52 weeks

Mean EASI score ± SD

30.02 ± 10.84

7.61 ± 4.77*

4.66 ± 3.25*

3.50 ± 2.88*

Mean percent change ± SD in EASI

 

74.90 ± 11.57

84.49 ± 9.05

88.14 ± 8.56

Mean NRS score ± SD

8.37 ± 1.72

3.36 ± 2.13*

3.24 ± 2.07*

2.80 ± 1.82*

Mean percent change ± SD in NRS

 

59.37 ± 5.42

59.51 ± 28.93

65.55 ± 23.05

Mean POEM ± SD

23.73 ± 4.35

9.99 ± 6.33*

9.00 ± 6.19*

7.34 ± 5.86*

Mean percent change ± SD in POEM

 

56.56 ± 27.34

59.95 ± 29.34

67.21 ± 29.34

Mean DLQI ± SD

22.37 ± 5.27

8.93 ± 6.59*

7.60 ± 6.86*

6.54 ± 5.74*

Mean percent change ± SD in DLQI

 

59.59 ± 29.23

61.01 ± 29.51

69.02 ± 27.61

  1. SD, standard deviation; EASI, Eczema Area and Severity Index; NRS, Numerical Rating Scale; POEM, patient-oriented eczema measure; DLQI, Dermatology Life Quality Index.
  2. *p value < 0.05, P value calculated by linear mixed model with discrete time points.
Back to article page